BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Elan Corporation PLC (ELN) Gets Director Opponents to Quit Board


9/20/2010 8:24:02 AM

DUBLIN, Sep 17, 2010 (BUSINESS WIRE) -- Elan Corporation, plc ("Elan") /quotes/comstock/13*!eln/quotes/nls/eln (ELN 4.83, 0.00, 0.00%) announced that at yesterday's meeting of the Elan Board of Directors, the Board unanimously accepted a report prepared by the United States law firm of McKenna Long & Aldridge, LLP based upon a review it conducted. McKenna Long, serving as independent counsel to the Board, reviewed a number of matters brought to the Board's attention by certain Directors.

In summary, McKenna Long's report found no legal breaches or other wrongdoing of any nature by Elan management, any member of its Board of Directors or its advisors. The Board approved the McKenna report in full and accepted its recommendations, including considering the feasibility of voluntarily complying with US domestic reporting requirements notwithstanding Elan's status as a foreign private issuer and adopting a US "best practices" conflicts policy.

Elan and Directors Vaughn Bryson and Jack Schuler have agreed to suspend the Irish High Court proceedings in light of the Board's support and acceptance of the McKenna report, and the ultimate implementation of its findings, and to bring a renewed focus on Elan's scientific mission.

Messrs Schuler and Bryson have expressed their satisfaction with the outcome of the McKenna process and have communicated their desire to resign from the Board. They will do so upon the election of a new Chairman over the course of the coming months or otherwise at the request of the Chairman, but in any event within 90 days.

About Elan

Elan Corporation, plc /quotes/comstock/13*!eln/quotes/nls/eln (ELN 4.83, 0.00, 0.00%) is a neuroscience-based biotechnology company committed to making a difference in the lives of patients and their families by dedicating itself to bringing innovations in science to fill significant unmet medical needs that continue to exist around the world. Elan shares trade on the New York and Irish Stock Exchanges. For additional information about the Company, please visit www.elan.com.


Read at BioSpace.com
Read at Reuters
Read at Financial Times
Read at AP
Read at Wall Street Journal

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES